Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Post by jopatcloon Sep 11, 2024 6:56am
63 Views
Post# 36218049

Take Heart 2024❤ Ventripoint has pioneered an AI technology

Take Heart 2024❤ Ventripoint has pioneered an AI technologyInteresting  Ventripoint has pioneered an AI technology that transforms ultrasound scans into MRI-quality images of the heart in minutes. Dr. Brian Soriano will share how this technology allows providers to capture high-quality images at a fraction of the cost and with significantly minimized risks compared to traditional MRI heart scans.


At Take Heart 2024, we will share topics that highlight work that leverages prediction for early recognition, uses precision for personalized care, and protects the quality of life through prevention.

Ventripoint has pioneered an AI technology that transforms ultrasound scans into MRI-quality images of the heart in minutes. Dr. Brian Soriano will share how this technology allows providers to capture high-quality images at a fraction of the cost and with significantly minimized risks compared to traditional MRI heart scans.
https://www.instagram.com/p/C_vTxFsMPYY/?img_index=2
<< Previous
Bullboard Posts
Next >>